

Registration No. 333-280342
333-269687
333-249983
333-258145

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO
FORM S-3 ON FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

FORTRESS BIOTECH, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

20-5157386

(I.R.S. Employer
Identification No.)

1111 Kane Concourse, Suite 301

Bay Harbor Islands, FL

(Address, including zip code, and telephone number,
including area code, of registrant's principal executive offices)

33154

(Zip Code)

Lindsay A. Rosenwald, M.D.

Executive Chairman,

Chief Executive Officer and President

1111 Kane Concourse, Suite 301

Bay Harbor Islands, FL 33154

(781) 652-4500

(Name, address, including zip code, and telephone number,
including area code, of agent for service)

Copy to:

Rakesh Gopalan

David S. Wolpa

Troutman Pepper Locke LLP

301 S College Street, Suite 3400

Charlotte, North Carolina 28202

(704) 916-2375

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box ☐

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

EXPLANATORY NOTE

The Registrant has previously filed:

- A registration statement on Form S-3 originally filed with the Securities and Exchange Commission (“SEC”) on June 20, 2024, File No. 333-280342 (as amended, “Registration Statement 280342”);
- A registration statement on Form S-3 originally filed with the SEC on February 10, 2023, File No. 333-269687 (as amended, “Registration Statement 269687”);
- A registration statement on Form S-3 originally filed with the SEC on November 10, 2023, File No. 333-258145 (as amended, “Registration Statement 258145”); and
- A registration statement on Form S-3 originally filed with the SEC on November 9, 2020, File No. 333-249983 (as amended, “Registration Statement 249983,” and, collectively with Registration Statement 280342, Registration Statement 269687 and Registration Statement 258145, the “Registration Statements,” and each, a “Registration Statement”);

The Registrant is not currently eligible to use a Form S-3 registration statement due to its failure to pay dividends on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock since the end of the previous fiscal year and the presence of accrued, but unpaid dividends on such series of preferred stock. Pursuant to Rule 429 under the Securities Act, the prospectus included in this Post-Effective Amendment No. 1 to Form S-3 on Form S-1 is a combined prospectus, and this registration statement constitutes a post-effective amendment to each of the Registration Statements and such post-effective amendments will become effective concurrently with the effectiveness of this post-effective amendment in accordance with Section 8(c) of the Securities Act. The Registration Statements registered, in relevant part, and this Post-Effective Amendment is being filed to continue the registration of:

- The offer and sale by certain selling stockholders who were previously holders of shares of 8% Cumulative Redeemable Perpetual Class B Preferred Stock (the “Urica Preferred Stock”) of Urica Therapeutics, Inc., a controlled subsidiary of the Registrant (“Urica”), of an aggregate of up to 1,987,250 shares of the Registrant’s common stock, par value \$0.001 per share (“Common Stock”), including
 - 80,160 shares of Common Stock originally issued as dividends under the Dividend Payment and Exchange Agreement dated as of December 27, 2022 (the “Dividend Agreement”) executed by Fortress Biotech, Inc. for the benefit of the holders of the Urica Preferred Stock, and pursuant to the terms of the Urica Preferred Stock, some of which shares have been sold since the original registration of such offer and sale;
 - 2,028,345 shares of Common Stock originally issued to the selling stockholders upon exchange of shares of Urica Preferred Stock with us pursuant to the terms of the Urica Preferred Stock, originally registered under Registration Statement 280342, some of which shares have been sold since the original registration of such offer and sale; and
 - 43,133 shares of Common Stock originally issued as dividends under the Dividend Agreement for the benefit of the holders of Urica Preferred Stock, originally registered under Registration Statement 269687, some of which shares have been sold since the original registration of such offer and sale;
- The offer and sale of up to 5,885,000 shares underlying warrants originally issued as part of units, each consisting of one share of Common Stock and one warrant, originally registered pursuant to the prospectus filed with the SEC under Rule 424(b)(5) on November 10, 2023, originally registered under Registration Statement 258145;
- The offer and sale of up to 3,303,305 shares underlying warrants originally issued as part of units, each consisting of one share of Common Stock and one warrant, originally registered pursuant to the prospectus filed with the SEC under Rule 424(b)(5) on December 29, 2023, originally registered under Registration Statement 258145; and
- The offer and sale by certain selling stockholders of up to 116,637 shares of Common Stock issuable upon the exercise of warrants, as amended, granted to Oaktree Fund Administration, LLC (“Oaktree”) and its affiliates under the senior secured credit agreement dated as of August 27, 2020, by and among Fortress Biotech, Inc., Oaktree as the administrative agent, and the other the lenders, originally registered under Registration Statement 249983.

All filing fees payable in connection with the registration of these securities were previously paid in connection with the filing of the Registration Statements.

The information in this prospectus is not complete and may be changed. Neither we nor the selling stockholders named in this prospectus may offer or sell these securities until the registration statement becomes effective. This prospectus is not an offer to sell these securities, and the selling stockholders named in this prospectus are not soliciting offers to buy these securities in any jurisdiction where the offer for sale is not permitted.

Subject To Completion, Dated March 31, 2025

PROSPECTUS



**9,188,305 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants
2,103,887 Shares of Common Stock for Resale by Selling Stockholders**

This prospectus relates to:

- the offer, sale and issuance by Fortress Biotech, Inc. (the “Company”) of up to 5,885,000 shares of our common stock, par value \$0.001 per share (“Common Stock”), at a purchase price of \$1.65 per share upon exercise of the outstanding warrants issued November 10, 2023 (the “November 2023 Warrants”);
- the offer, sale and issuance by the Company of up to 3,303,305 shares of our Common Stock, at a purchase price of \$3.21 per share upon exercise of the outstanding warrants issued December 29, 2023 (the “December 2023 Warrants”);
- the resale by certain selling stockholders (the “Oaktree Selling Stockholders”) of up to 116,637 shares of Common Stock (the “Oaktree Warrant Shares”) issuable upon the exercise of outstanding warrants, as amended (the “Oaktree Warrants”) granted to Oaktree Fund Administration, LLC (“Oaktree”) and its affiliates under the senior secured credit agreement dated as of August 27, 2020, by and among the Company, Oaktree as the administrative agent, and the other the lenders (the “Oaktree Credit Agreement”);

- the resale by certain selling stockholders who were previously holders of shares of 8% Cumulative Redeemable Perpetual Class B Preferred Stock (the “Urica Preferred Stock”) of Urica Therapeutics, Inc. (“Urica”) of an aggregate of 1,987,250 shares of Common Stock, including the resale:
 - by such holders (the “2023 Urica Selling Stockholders”) of up to 43,133 shares of Common Stock (the “2023 Shares”), originally issued as dividends under the Dividend Payment and Exchange Agreement dated as of December 27, 2022 (the “Dividend Agreement”) executed by the Company for the benefit of the holders of Urica Therapeutics, Inc. (“Urica”) to former holders of the 8% Cumulative Redeemable Perpetual Class B Preferred Stock (the “Urica Preferred Stock”), some of which shares have been sold since the original registration of such offer and sale; and
 - by such holders (the “2024 Urica Selling Stockholders”) of up to 80,160 shares of Common Stock originally issued as dividends and the 2,028,345 shares of Common Stock (together, the “2024 Shares”), issuable upon exchange of the Urica Preferred Stock, in each case, pursuant to the terms of the Urica Preferred Stock and the Dividend Agreement, some of which shares have been sold since the original registration of such offer and sale.

Accordingly, by means of the registration statement of which this prospectus forms a part, we are registering:

- the offer, sale and issuance of Common Stock (the “Warrant Shares”) upon the exercise of the November 2023 Warrants and the December 2023 Warrants (collectively, the “Warrants”); and
- the offer, sale and resale, from time to time, of the Oaktree Warrant Shares, the 2023 Shares and the 2024 Shares (collectively, the “Resale Shares”) by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the section “*The Selling Stockholders*,” or their pledgees, donees, transferees or other successors in interest, from time to time.

The Selling Stockholders may resell or dispose of the Resale Shares, or interests therein, at fixed prices, at prevailing market prices at the time of sale or at prices negotiated with purchasers, to or through underwriters, broker-dealers, agents, or through any other means described in the section of this prospectus titled “*Plan of Distribution*.” Each Selling Stockholder will each bear their respective commissions and discounts, if any, attributable to the sale or disposition of the Resale Shares, or interests therein, held by such Selling Stockholder. We will bear all costs, expenses and fees in connection with the registration of the resale of the Resale Shares. We will not receive any of the proceeds from the sale of the Resale Shares by the Selling Stockholders. We will receive proceeds from our issuance of Common Stock upon any cash exercise of the Warrants. If all of the Warrants are exercised for cash (meaning we issue the maximum possible number of shares of Common Stock upon exercise of the Warrants), we will receive gross cash proceeds of approximately \$20,313,859. There can be no assurance that any Warrant holder will exercise Warrants, especially since, as of the date of this prospectus, none of the Warrants are in-the-money.

Our Common Stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “FBIO.” On March 28, 2025, the last reported sale price of our Common Stock was \$1.61 per share. You are urged to obtain current market quotations for our Common Stock.

Investing in our securities involves risks. You should review carefully the risks and uncertainties described under the heading “*Risk Factors*” contained in this prospectus and under similar headings in the other documents that are incorporated by reference into this prospectus as described on page 4 of this prospectus.

Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this Prospectus is , 2025

TABLE OF CONTENTS

Prospectus	Page
ABOUT THIS PROSPECTUS	i
FORWARD-LOOKING STATEMENTS	ii
SUMMARY	1
THE OFFERING	3
RISK FACTORS	4
USE OF PROCEEDS	4
THE SELLING STOCKHOLDERS	6
DESCRIPTION OF SECURITIES BEING REGISTERED	10
CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS	13
PLAN OF DISTRIBUTION	19
LEGAL MATTERS	21
EXPERTS	21
WHERE YOU CAN FIND MORE INFORMATION	21
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE	21

ABOUT THIS PROSPECTUS

This prospectus provides you with a general description of the Warrant Shares offered by us and the Resale Shares that may be resold by the Selling Stockholders. In certain circumstances, we may provide a prospectus supplement that will contain specific information about the terms of a particular offering. We also may provide a prospectus supplement to add information to, or update or change information contained in, this prospectus. To the extent there is a conflict between the information contained in this prospectus and any prospectus supplement, you should rely on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date — for example, a document incorporated by reference in this prospectus or any prospectus supplement — the statement in the later-dated document modifies or supersedes the earlier statement.

You should read both this prospectus and any applicable prospectus supplement together with the additional information about our company to which we refer you in the sections of this prospectus titled “*Where You Can Find More Information*” and “*Incorporation of Certain Documents by Reference*.” You should rely only on the information contained in or incorporated by reference into this prospectus and any prospectus supplement. Neither we nor the Selling Stockholders have authorized any dealer, salesperson or other person to provide you with different information. You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the date on the front of those documents or that any document incorporated by reference is accurate as of any date other than its filing date. You should not consider this prospectus to be an offer or solicitation relating to the Warrant Shares or the Resale Shares in any jurisdiction in which such an offer or solicitation relating to the Warrant Shares or the Resale Shares is not authorized. Furthermore, you should not consider this prospectus to be an offer or solicitation relating to the Warrant Shares or the Resale Shares if the person making the offer or solicitation is not qualified to do so, or if it is unlawful for you to receive such an offer or solicitation.

Unless the context indicates otherwise, when we refer to “Fortress,” “we,” “our,” “us” and the “Company” in this prospectus, we may refer to Fortress Biotech, Inc. individually, to one or more of its subsidiaries and/or partner companies, or to all such entities as a group, as dictated by context. When we refer to “you,” we mean the potential holders of the Warrant Shares or purchasers of the Resale Shares.

FORWARD-LOOKING STATEMENTS

This prospectus, including the documents that we incorporate by reference, contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this prospectus, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “should,” “would” and similar expressions, as they relate to us, are intended to identify forward-looking statements.

These statements are based on current expectations, estimates and projections made by management about our business, our industry and other conditions affecting our financial condition, results of operations or business prospects. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties. Factors that could cause such outcomes and results to differ include, but are not limited to, risks and uncertainties arising from:

- our growth strategy;
- financing and strategic agreements and relationships;
- our need for substantial additional funds and uncertainties relating to financings;
- our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis;
- our ability to attract, integrate and retain key personnel;
- the early stage of products under development;
- the results of research and development activities;
- uncertainties relating to preclinical and clinical testing;
- the ability to secure and maintain third-party manufacturing, marketing and distribution of our and our partner companies’ products and product candidates;
- government regulation;
- patent and intellectual property matters; and
- competition.

You should read this prospectus and the documents that we reference herein completely and with the understanding that our actual future results may be materially different from what we currently expect. You should assume that the information appearing in this prospectus and any document incorporated by reference is accurate as of its date only. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this prospectus, any accompanying prospectus supplement and any document incorporated herein by reference, and particularly our forward-looking statements, by these cautionary statements.

SUMMARY

This summary highlights selected information from this prospectus and does not contain all of the information that may be important to you in making an investment decision. This summary is qualified in its entirety by the more detailed information included elsewhere in this prospectus and/or incorporated by reference herein. Before making your investment decision with respect to our securities, you should carefully read this entire prospectus, including the information in our filings with the Securities and Exchange Commission (“SEC”) incorporated by reference into this prospectus.

Our Business

Overview

Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holding and dividend and royalty revenue streams. Fortress works in concert with its extensive network of key opinion leaders to identify and evaluate promising products and product candidates for potential acquisition. We have executed arrangements in partnership with some of the world’s foremost universities, research institutes and pharmaceutical companies, including City of Hope National Medical Center, Fred Hutchinson Cancer Center, Dana-Farber Cancer Institute, Nationwide Children’s Hospital, Cincinnati Children’s Hospital Medical Center, Columbia University, the University of Pennsylvania, AstraZeneca plc., and Dr. Reddy’s Laboratories, Ltd.

Business Strategy

Following the exclusive license or other acquisition of the intellectual property underpinning a product or product candidate, Fortress leverages its business, scientific, regulatory, legal and financial expertise to help the partners achieve their goals. Partner companies then assess a broad range of strategic arrangements to accelerate and provide additional funding to support research and development, including joint ventures, partnerships, out-licensings, and public and private financings. To date, four partner companies are publicly traded, and three have consummated strategic partnerships with industry leaders, including AstraZeneca plc, as successor-in-interest to Alexion Pharmaceuticals, Inc. (“AstraZeneca”), and Sentyln Therapeutics, Inc. (“Sentyln”).

Our subsidiary and partner companies that are pursuing development and/or commercialization of biopharmaceutical products and product candidates are: Avenue Therapeutics (Nasdaq: ATXI, “Avenue”), Baergic Bio, Inc. (“Baergic,” a subsidiary of Avenue), Cellvation, Inc. (“Cellvation”), Checkpoint Therapeutics, Inc. (Nasdaq: CKPT, “Checkpoint”), Cyprium Therapeutics, Inc. (“Cyprium”), Helocyte, Inc. (“Helocyte”), Journey Medical Corporation (Nasdaq: DERM, “Journey” or “JMC”), Mustang Bio, Inc. (Nasdaq: MBIO, “Mustang”) and Oncogenuity, Inc. (“Oncogenuity”).

November 2023 Warrants

On November 14, 2023, we closed a public offering of an aggregate of 5,885,000 units, consisting of one share of Common Stock and one warrant to purchase one share of Common Stock, at a public offering price of \$1.70 per unit. The November 2023 Warrants were immediately exercisable at a price of \$1.70 per share and expire five years from the date of issuance. In September 2024, the Company closed an offering of common stock at a price of \$1.65 per share, which resulted in an adjustment to the exercise price of the November 2023 warrants from \$1.70 per share to \$1.65 per share pursuant to a one-time price reset provision in the November 2023 warrants. Certain directors and officers of the Company participated in the offering and purchased an aggregate amount of approximately \$2.9 million of units at the same purchase price. The gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately \$10.0 million.

December 2023 Warrants

On January 3, 2024, we closed a public offering of an aggregate of 3,303,305 units, consisting of one share of Common Stock and one warrant to purchase one share of Common Stock, at a public offering price of \$3.33 per unit. The December 2023 Warrants were immediately exercisable at a price of \$3.21 per share and expire five years from the date of issuance. The gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately \$11.0 million.

Grant of Oaktree Warrants

On August 27, 2020, we entered into the Oaktree Credit Agreement, in connection with which we granted to the Oaktree Selling Stockholders warrants to purchase 1,749,450 shares of Common Stock at an exercise price of \$3.20 per share. Additionally, on June 13, 2023, the Company entered into a Letter Agreement (the “2023 Letter Agreement”) by and among the Company, Oaktree and certain of its affiliates, pursuant to which the Company agreed to lower the exercise price of the existing warrants to \$0.5424 per share and issue amended and restated warrants reflecting the new exercise price, as consideration for the warrant holders’ agreement to permit the Company and/or certain of its subsidiaries to take certain actions. The Oaktree Warrants became exercisable on June 13, 2023 and expire August 27, 2030. The Company effected a reverse stock split on October 9, 2023, pursuant to which the number of shares issuable upon the exercise of the Oaktree Warrants decreased to 116,637 and the exercise price increased to \$8.136 per share. Pursuant to the anti-dilution adjusted mechanism of the Oaktree Warrants, the number of shares issuable upon the exercise of the Oaktree Warrants increased from 116,637 shares to 131,087 shares (the “Additional Shares”) and the exercise price decreased to \$7.2392 per share. The resale of the Additional Shares was registered on Form S-1 originally filed with the SEC on September 27, 2024, File No. 333-282384.

In addition, in connection with the Oaktree Credit Agreement, we entered into a registration rights agreement with the Oaktree Selling Stockholders (the “Oaktree Registration Rights Agreement”), in which we agreed to prepare and file with the SEC a registration statement with respect to resales of the securities purchased by the Oaktree Selling Stockholders in connection with the Oaktree Credit Agreement. Accordingly, as required by the Registration Rights Agreement, the registration statement of which this prospectus is a part relates to the offer and resale of the Oaktree Warrant Shares issued to the Oaktree Selling Stockholders in connection with the Oaktree Credit Agreement.

Dividend Payment and Exchange Agreement

On December 27, 2022, we executed the Dividend Agreement for the benefit of the holders of Urica Preferred Stock, pursuant to which we agreed to (i) pay cumulative dividends on the Urica Preferred Stock in shares of our Common Stock and (ii) issue new shares of Common Stock to the holders of the Urica Preferred Stock, in exchange for their mandatory tender to us of their shares of Urica Preferred Stock, upon the occurrence of certain conditions set forth in the Certificate of Designations of Rights and Preferences for the Urica Preferred Stock.

In addition, in connection with the Dividend Agreement, we entered into a registration rights agreement with the 2023 Urica Selling Stockholders and the 2024 Urica Selling Stockholders (the “Urica Registration Rights Agreement”) in which we agreed to prepare and file with the SEC a registration statement with respect to resales of the Common Stock issued to the 2023 Urica Selling Stockholders and the 2024 Urica Selling Stockholders (i) as dividends on the Urica Preferred Stock and (ii) upon exchange of their shares of Urica Preferred Stock. Accordingly, as required by the Urica Registration Rights Agreement, the registration statement of which this prospectus is a part relates to the offer and resale of the Common Stock issued and issuable to the Selling stockholders under the terms of the Urica Preferred Stock and in connection with the Dividend Agreement.

Corporate Information

Our principal executive offices are located at 1111 Kane Concourse Suite 301 Bay Harbor Islands, FL 33154, and our telephone number is 781-652-4500. We

maintain a website on the Internet at www.fortressbiotech.com and our e-mail address is info@fortressbiotech.com. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act are available, free of charge, under the Investor Relations tab of our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC also maintains an Internet website located at www.sec.gov that contains the information we file or furnish electronically with the SEC. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this prospectus, and you should not consider it part of this prospectus.

THE OFFERING

Issuer:	Fortress Biotech, Inc.
Securities Offered:	<p>This prospectus relates to:</p> <ul style="list-style-type: none">the offer, sale and issuance by the Company, of up to 5,885,000 shares of Common Stock, at a purchase price of \$1.65 per share upon exercise of the November 2023 Warrants;the offer, sale and issuance by the Company of up to 3,303,305 shares of Common Stock, at a purchase price of \$3.21 per share upon exercise of the December 2023 Warrants;the resale by the Oaktree Selling Stockholders of up to 116,637 shares of Common Stock issuable upon the exercise of the Oaktree Warrants;the resale by the 2023 Urica Selling Stockholders and 2024 Urica Selling Stockholders of an aggregate up to 1,987,250 shares of Common Stock originally issued as dividends to former holders of the Urica Preferred Stock or upon exchange of the Urica Preferred Stock.
Shares of Common Stock Outstanding Prior to this Offering⁽¹⁾:	29,553,840 shares of Common Stock
Shares of Common Stock Outstanding Assuming the Exercise of All Warrants⁽¹⁾:	40,846,032 shares of Common Stock
Terms of the Offering	The Selling Stockholders will each determine when and how they will sell the Resale Shares offered in this prospectus, as described in the “ <i>Plan of Distribution</i> .”
Use of Proceeds	We intend to use the net proceeds from the exercise of the Warrants for our operations, including, but not limited to, general corporate purposes, which may include research and development expenditures, clinical trial expenditures, license or acquisition of new products, and working capital. There can be no assurance that any Warrant holder will exercise Warrants, especially since, as of the date of this prospectus, none of the Warrants are in-the-money. We will not receive any proceeds from the sale of the Resale Shares by the Selling Stockholders in this offering. See “ <i>Use of Proceeds</i> .”
Risk Factors	See “ <i>Risk Factors</i> ” incorporated by reference into this prospectus from our most current Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, for a discussion of certain factors you should carefully consider before deciding to invest in shares of our Common Stock.
Nasdaq Capital Market Symbol	FBIO

(1) The number of shares of Common Stock is based on 29,553,840 shares of our Common Stock outstanding as of March 27, 2025, and excludes as of that date:

- 1,064,039 shares of Common Stock underlying unvested Restricted Stock Units;
- 1,151,042 shares of Common Stock underlying unvested deferred Restricted Stock Units;
- 361,846 shares of Common Stock underlying deferred Restricted Stock Awards;
- 18,896 shares of Common Stock issuable upon the exercise of stock options with a weighted average exercise price of \$20.55 per share; and
- 14,406,201 shares of Common Stock issuable upon exercise of outstanding warrants with a weighted average exercise price of \$2.15 per share.

Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of the outstanding options or warrants or settlement of outstanding restricted stock units, described above.

RISK FACTORS

Investing in our Common Stock involves a high degree of risk. Our business is influenced by many factors that are difficult to predict, involve uncertainties that may materially affect actual results and are often beyond our control. You should consider carefully the risks and uncertainties under the heading “*Risk Factors*” in our [Annual Report on Form 10-K for the fiscal year ended December 31, 2024](#), which are each incorporated by reference in this prospectus, and the risks, uncertainties and other information set forth in the reports and other materials filed or furnished by our partners and affiliates Journey, Checkpoint, Mustang, and Avenue with the SEC, as well as any amendment or update to our risk factors in subsequent filings with the SEC, and other information in our consolidated financial statements, all of which are incorporated by reference into this prospectus, before deciding to invest in our Common Stock. If any of the described risks incorporated by reference hereto or the risks included in the public filings of Journey, Checkpoint, Mustang or Avenue were to materialize, our business, financial condition, results of operations, and future growth prospects could be materially and adversely affected. In that event, the market price of our Common Stock could decline, and you could lose part of or all of your investment in our Common Stock. See the section of this prospectus titled “*Where You Can Find More Information*.”

USE OF PROCEEDS

The gross proceeds that we receive from this offering will depend upon the number of Warrants exercised and the exercise price of the Warrants exercised. If all of the Warrants are exercised for cash (meaning we issue the maximum possible number of shares of Common Stock upon exercise of the Warrants), we will receive gross cash proceeds of approximately \$20,313,859. There can be no assurance that any Warrant holder will exercise Warrants, especially since, as of the date of this prospectus, none of the Warrants are in-the-money. We intend to use the net proceeds from exercises of the Warrants for our operations, including, but not limited to, general corporate purposes, which may include research and development expenditures, clinical trial expenditures, license or acquisition of new products, and working capital.

We will not receive any proceeds from the sale of the Resale Shares covered by this prospectus and any accompanying prospectus supplement. All proceeds from the sale of the Resale Shares will be for the respective accounts of the Selling Stockholders named herein.

We will bear all other costs, fees and expenses incurred in effecting the registration of the offer and sale of the Warrant Shares and the Resale Shares covered by this prospectus and any accompanying prospectus supplement, including, without limitation, all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our accountants. Each Selling Stockholder will pay any discounts, commissions, and fees of underwriters, selling brokers, dealer managers or similar securities industry professionals incurred by such Selling Stockholder in disposing of the Resale Shares covered by this prospectus.

DETERMINATION OF OFFERING PRICE

The exercise prices of the Warrants were negotiated between us and the investors in the respective offerings based on the trading of our Common Stock prior to the offering, among other things. Other factors considered in determining the exercise price of the Warrants that we sold included our history and prospects, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, the general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant.

We cannot currently determine the price or prices at which the shares of Common Stock may be sold by the Selling Stockholders under this prospectus.

DIVIDEND POLICY

We have never paid cash dividends to the holders of our Common Stock and currently intend to retain all available funds and any future earnings to fund the development and expansion of our business. We do not anticipate paying any cash dividends to the holders of our Common Stock in the foreseeable future. Investors should not purchase our Common Stock with the expectation of receiving cash dividends. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant.

DILUTION

Our net tangible book value as of December 31, 2024 was approximately \$(33.5) million, or \$(1.20) per share of Common Stock. Net tangible book value (deficit) per share is calculated by subtracting our total liabilities from our total tangible assets, which is total assets less intangible assets, and dividing this amount by the number of shares of Common Stock outstanding. After giving effect to the exercise of the Warrants for the underlying 9,188,305 shares of Common Stock for an aggregate exercise price of \$20,313,859, and after deducting any offering expenses payable by us, we would have had a net tangible book value as of December 31, 2024 of approximately \$(13.2) million, or \$(0.36) per share of Common Stock. This represents an immediate increase in net tangible book value of \$0.84 per share to our existing stockholders and an immediate dilution in net tangible book value to the holders of the November 2023 Warrants and the December 2023 Warrants. The following table illustrates this dilution:

Exercise Price of the November 2023 Warrants		\$	1.65
Exercise Price of the December 2023 Warrants		\$	3.21
Net tangible book value (deficit) per share as of December 31, 2024	\$	(1.20)	
Increase per share attributable to the exercise of all the Warrants	\$	0.84	
As adjusted net tangible book per share after the exercise of all the Warrants	\$	(0.36)	
Dilution in net tangible book value per share to investors exercising November 2023 Warrants and December 2023 Warrants	\$	2.57	

The number of shares of Common Stock is based on 27,908,839 shares of our Common Stock outstanding as of December 31, 2024, and excludes as of that date:

- 1,141,164 shares of Common Stock underlying unvested Restricted Stock Units;
- 1,239,583 shares of Common Stock underlying unvested deferred Restricted Stock Units;
- 176,660 shares of Common Stock underlying deferred Restricted Stock Awards;
- 558,896 shares of Common Stock issuable upon the exercise of stock options with a weighted average exercise price of \$2.32 per share; and
- 14,406,201 shares of Common Stock issuable upon exercise of outstanding warrants with a weighted average exercise price of \$2.15 per share.

To the extent our outstanding options and warrants (other than the Warrants) are exercised, you may experience further dilution. The above illustration of dilution per share to investors participating in this offering assumes no exercise of outstanding options or outstanding warrants to purchase shares of our Common Stock (other than the Warrants). The illustration also assumes no further issuance of shares of our Common Stock in payment of contingent consideration to holders of our outstanding contingent value rights or others. The exercise of outstanding options and warrants having an exercise price less than the exercise prices of the Warrants, or our payment to our contingent value rights holders or others of Common Stock valued at less than the offering price of shares in this offering, would further increase dilution to investors in this offering.

While the above table assumes full exercise of all of the Warrants, there can be no assurance that any Warrant holder will exercise Warrants, especially since, as of the date of this prospectus, none of the Warrants are in-the-money.

THE SELLING STOCKHOLDERS

The shares of Common Stock being offered by the Selling Stockholders are those previously issued to the 2023 Urica Selling Stockholders and the 2024 Urica Selling Stockholders as dividends on, or upon exchange of, the Urica Preferred Stock under the terms of the Dividend Agreement and the Urica Preferred Stock, and those issuable to Oaktree and certain of its affiliates upon exercise of the Oaktree Warrants. For additional information regarding the issuances of those shares of Common Stock and Oaktree Warrants, see “Summary” above. We are registering the resale of the shares of Common Stock in order to permit the Selling Stockholders to offer the shares for resale from time to time. Except for their ownership of the shares of our Common Stock and their prior ownership of Urica Preferred Stock, the 2023 Urica Selling Stockholders and the 2024 Urica Selling Stockholders have not had any material relationship with us within the past three years. Except for their ownership of the Oaktree Warrants as well as their

lending relationship with us, none of Oaktree and its affiliates have had any material relationship with us within the past three years.

The Resale Shares offered by this prospectus may be sold from time to time on Nasdaq, in privately negotiated transactions or otherwise. We have agreed to prepare and file amendments and supplements to the registration statement to the extent necessary to keep the registration statement effective for the period of time required under our agreement with the Selling Stockholders.

All information with respect to the Selling Stockholders' ownership of the Resale Shares has been furnished by or on behalf of the Selling Stockholders and is as of March 27, 2025. The percentage ownership data is based on 29,533,840 shares of Common Stock issued and outstanding as of March 27, 2025. We believe, based on information supplied by the Selling Stockholders, that except as may otherwise be indicated in the table below, the Selling Stockholders and their affiliates listed in any footnote to the table below have sole voting and dispositive power with respect to the shares of Common Stock reported as beneficially owned by them.

The aggregate number of shares of Common Stock that the Selling Stockholders may offer and sell pursuant to this prospectus is based upon (i) the number of shares of Common Stock that may be issued to the Oaktree Selling Stockholders upon the exercise of the Oaktree Warrants; (ii) the number of shares of Common Stock issued to the 2023 Urica Selling Stockholders and the 2024 Urica Selling Stockholders as dividends on, and upon exchange of, the Urica Preferred Stock pursuant to the terms of the Urica Preferred Stock and the Dividend Agreement. The Selling Stockholders may sell some, all or none of the Resale Shares. We do not know how long the Selling Stockholders will hold the Resale Shares before selling them, and we currently have no agreements, arrangements or understandings with any Selling Stockholders regarding the sale or other disposition of any of the Resale Shares or any other shares of Common Stock. The Resale Shares may be offered and sold from time to time by the Selling Stockholders pursuant to this prospectus.

Because the Selling Stockholders may sell some or all of the Resale Shares included in this prospectus, and because there are currently no agreements, arrangements or understandings with respect to the sale of any of the Resale Shares, no estimate can be given as to the number of shares of Common Stock available for resale hereby that will be held by the Selling Stockholders in the future. In addition, the Selling Stockholders may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose of, at any time and from time to time, Resale Shares they hold in transactions exempt from the registration requirements of the Securities Act after the date on which they provided the information set forth in the table below. We have, therefore, assumed for the purposes of the following table, that the Selling Stockholders will sell all of the Resale Shares owned beneficially by them and their affiliates listed in any footnote to the table below that are covered by this prospectus, but not any other shares of Common Stock they may beneficially own.

Selling Stockholder Information:				
	Shares Owned Immediately Prior to the Offering ⁽²⁾	Shares Being Offered for Resale Under this Prospectus ⁽³⁾	Number of Shares Beneficially Owned After Sale of Shares ⁽⁴⁾	Percentage of Outstanding Shares of Common Stock Beneficially Owned Immediately Following the Sale of Shares ⁽⁵⁾
Selling Stockholders⁽¹⁾				
Oaktree Selling Stockholders				
Oaktree-TCDRS Strategic Credit, LLC	5,540	5,540	—	—
Exelon Strategic Credit Holdings, LLC	3,319	3,319	—	—
Oaktree-NGP Strategic Credit, LLC	5,562	5,562	—	—
Oaktree-Minn Strategic Credit, LLC	2,687	2,687	—	—
Oaktree-Forrest Multi-Strategy, LLC – Series A	4,528	4,528	—	—
Oaktree-TBMR Strategic Credit Fund C, LLC	2,623	2,623	—	—
Oaktree-TBMR Strategic Credit Fund F, LLC	4,092	4,092	—	—
Oaktree-TBMR Strategic Credit Fund G, LLC	6,701	6,701	—	—
Oaktree-TSE 16 Strategic Credit, LLC	5,113	5,113	—	—
INPRS Strategic Credit Holdings, LLC	2,240	2,240	—	—
Oaktree Gilead Investment Fund AIF (Delaware), L.P.	20,043	20,043	—	—
Oaktree Huntington-GCF Investment Fund (Direct Lending AIF), L.P.	1,954	1,954	—	—
Oaktree Strategic Income II, Inc.	5,720	5,720	—	—
Oaktree Specialty Lending Corporation	16,224	16,224	—	—
Oaktree Strategic Income Corporation	5,857	5,857	—	—
Oaktree PRE Life Sciences Fund, L.P.	24,434	24,434	—	—
2023 and 2024 Urica Selling Stockholders				
Alejandro J Messmacher	63,539	63,539	—	—
Andrew R. McDonald	12,055	12,055	—	—
Anthony Van Hoven	127,082	127,082	—	—
Brian Dumann	79,385	79,385	—	—
Bryan K. Melvin	31,733	31,733	—	—
Claude Roussel	12,705	12,705	—	—
Doug Tiffan	15,864	15,864	—	—
Douglas Battaglia	52,958	52,958	—	—
Geoffrey C. Maddock	31,733	31,733	—	—
Gregory Konsor	176	176	—	—
Hochman Family LLLP ⁽⁶⁾	15,882	15,882	—	—
James Ellinwood	95,237	95,237	—	—
John and Jane Herbert Revocable Trust ⁽⁷⁾	95,311	95,311	—	—
JSGM Trust ⁽⁸⁾	19,059	19,059	—	—
Keith R. Schroeder	95,252	95,252	—	—
Kevin Stein	635,428	635,428	—	—
Leon J Goldschmidt	9,528	9,528	—	—
Lori A Kelley	19,059	19,059	—	—
Mark A Bradley	7,941	7,941	—	—
Mark Wiltse	31,768	31,768	—	—
Michael Thielen	12,705	12,705	—	—
MONEST LLC ⁽⁹⁾	63,456	63,456	—	—
Paul J Glauber	36,850	36,850	—	—
Paul E Hoyle	15,882	15,882	—	—
Rick and Kristine Zabel	15,864	15,864	—	—

Robert W. Tully and Brenda E. Tully	47,652	47,652	—	—
Roger and Christie Gildehaus	63,539	63,539	—	—
Steven Zaloga	941	941	—	—
T. Mark Sledge	17,152	17,152	—	—
The Holroyd Family Revocable Trust ⁽¹⁰⁾	216	216	—	—
Michael C. Fox Revocable Trust 05/05/2005 ⁽¹¹⁾	37,445	37,445	—	—
Thomas E. Vandenberg	51,408	51,408	—	—
Tom Kreszl	15,882	15,882	—	—
Vincent C Shoemaker	63,539	63,539	—	—
Vito LaVopa	1,000	1,000	—	—
William Bonifas	12,691	12,691	—	—
William Stocker III	15,864	15,864	—	—
Yuyun Li and David Norwood	63,469	63,469	—	—

* Less than 1%.

- (1) The principal business address and address for notice to the Selling Stockholders will be the address set forth in our books and records.
- (2) This includes, for each Selling Stockholder, any shares of Common Stock beneficially owned by such holder acquired in one or more transactions separate and unrelated from the holder's ownership of any of the Oaktree Warrant Shares, the 2023 Shares and/or the 2024 Shares, as applicable to such holder.
- (3) This includes, for each Selling Stockholder, (i) Oaktree Warrant Shares being sold hereunder, (ii) the 2023 Shares being sold hereunder and/or (iii) the 2024 Shares being sold hereunder, as applicable to such holder.
- (4) Assumes the Selling Stockholders sell all of the shares of Common Stock being offered by this prospectus.
- (5) Percentage calculated based upon the assumption that the Selling Stockholders sell all of the shares of Common Stock offered by this prospectus.
- (6) Lawrence Hochman is the controlling person and holds the voting and dispositive power over the shares held by Hochman Family LLLP.
- (7) John Herbert is the controlling person and holds the voting and dispositive power over the shares held by the John and Jane Herbert Revocable Trust.
- (8) Joel Miklas is the controlling person and holds the voting and dispositive power over the shares held by the JSGM Trust.
- (9) Donald Kanak is the controlling person and holds the voting and dispositive power over the shares held by MONEST LLC.
- (10) Douglas Holroyd is the controlling person and holds the voting and dispositive power over the shares held by The Holroyd Family Revocable Trust.
- (11) Michael Fox is the controlling person and holds the voting and dispositive power over the shares held by Michael C. Fox Revocable Trust 05/05/2005.

Relationship with Oaktree Selling Stockholders

Oaktree Credit Agreement

As discussed above under the section titled “Summary — Grant of Oaktree Warrants,” on August 27, 2020, we entered into the Oaktree Credit Agreement, in connection with which we granted to the Oaktree Selling Stockholders warrants to purchase 1,749,450 shares of Common Stock at an exercise price per share of \$3.20.

On June 13, 2023, we entered into the 2023 Letter Agreement with Oaktree and certain of its affiliates, pursuant to which we agreed to lower the exercise price of the existing warrants to \$8.136 per share (adjusted for the reverse stock split, which reduced the number of shares issuable upon the exercise of the Oaktree Warrants to 116,637) and issue amended and restated warrants reflecting the new exercise price. Pursuant to the anti-dilution adjusted mechanism of the Oaktree Warrants, the number of shares issuable upon the exercise of the Oaktree Warrants increased from 116,637 shares to 131,087 shares and the exercise price decreased to \$7.2392 per share. The resale of the Additional Shares were registered on Form S-1 originally filed with the SEC on September 27, 2024, File No. 333-282384.

Oaktree Registration Rights Agreement

Pursuant to the Oaktree Registration Rights Agreement with the Oaktree Selling Stockholders, we agreed to prepare and file with the SEC the registration statement of which this prospectus forms a part that permits the resale of the Securities and, subject to certain exceptions, use reasonable best efforts to keep such registration statement effective under the Securities Act until (i) all Oaktree Warrant Shares registered by the registration statement have been sold, transferred or otherwise disposed of by the selling stockholders, (ii) the Oaktree Warrant Shares are sold, transferred or otherwise disposed of pursuant to Rule 144 of the Securities Act, or (iii) the Oaktree Warrant Shares have become eligible for sale by the Oaktree Selling Stockholders pursuant to Rule 144 without any restriction on the volume or manner of such sale and all restrictive legends and stop transfer instructions have been removed with respect to all book entries representing the Oaktree Warrant Shares.

Oaktree Warrants

The Oaktree Warrants became exercisable on June 13, 2023 and will expire on August 27, 2030 at a price per share equal to \$7.2392 per share, subject to certain adjustments.

Except as described above, neither the Oaktree Selling Stockholders nor any persons having control over such Oaktree Selling Stockholders have held any position or office with us or our affiliates within the last three years or has had a material relationship with us or any of our predecessors or affiliates within the past three years, other than as a result of the ownership of shares of our common stock or other securities.

Relationship with the 2023 Urica Selling Stockholders and 2024 Urica Selling Stockholders

Dividend Payment and Exchange Agreement

As discussed above under the section “Summary — Dividend Payment and Exchange Agreement,” on December 27, 2022, we executed the Dividend Agreement for the benefit of the holders for the Urica Preferred Stock, pursuant to which we agreed to pay cumulative dividends on the Urica Preferred Stock in shares of our Common Stock.

Urica Registration Rights Agreement

Pursuant to the Urica Registration Rights Agreement with the 2023 Urica Selling Stockholders and the 2024 Urica Selling Stockholders, we agreed to prepare and file with the SEC the registration statement, of which this prospectus forms a part, that permits the resale of the Common Stock and, subject to certain exceptions, to use reasonable best efforts to keep such registration statement effective under the Securities Act until (i) all Common Stock registered by the registration statement has been sold, transferred or

otherwise disposed of by the 2023 Urica Selling Stockholders and the 2024 Urica Selling Stockholders, (ii) the Common Stock is sold, transferred or otherwise disposed of pursuant to Rule 144 of the Securities Act, or (iii) the Common Stock has become eligible for sale by the 2023 Urica Selling Stockholders and the 2024 Urica Selling Stockholders pursuant to Rule 144 without any restriction on the volume or manner of such sale and all restrictive legends and stop transfer instructions have been removed with respect to all book entries representing the Common Stock.

Except as described above, neither the 2023 Urica Selling Stockholders nor the 2024 Urica Selling Stockholders, nor any persons having control over such 2023 Urica Selling Stockholders and 2024 Urica Selling Stockholders, have held any position or office with us or our affiliates within the last three years or has had a material relationship with us or any of our predecessors or affiliates within the past three years, other than as a result of the ownership of shares of our Common Stock or other securities.

DESCRIPTION OF SECURITIES BEING REGISTERED

We are registering the issuance of 9,188,305 shares of Common Stock upon the exercise of the Warrants. We are also registering the public offer and resale of 2,103,887 shares of our Common Stock, which consists of the 2023 Shares, 2024 Shares and the Oaktree Warrant shares issuable in connection with the Oaktree Warrants.

Common Stock

The Company's Certificate of Incorporation, as amended, authorizes the Company to issue up to 200,000,000 shares of Common Stock. Our Common Stock is traded on The Nasdaq Capital Market under the symbol "FBIO."

The terms, rights, preference and privileges of the Common Stock are as follows:

Voting Rights

Each holder of Common Stock is entitled to one vote per share of Common Stock held on all matters submitted to a vote of the stockholders, including the election of directors. The Company's certificate of incorporation and bylaws do not provide for cumulative voting rights.

Dividends

Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of the Company's outstanding shares of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Company's Board of Directors out of legally available funds.

Liquidation

In the event of the Company's liquidation, dissolution or winding up, holders of Common Stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of the Company's debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.

Rights and Preference

Holders of the Company's Common Stock have no preemptive, conversion or subscription rights, and there is no redemption or sinking fund provisions applicable to our Common Stock. The rights, preferences and privileges of the holders of Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of the Company's preferred stock that are or may be issued.

Fully Paid and Nonassessable

All of the Company's outstanding shares of Common Stock are fully paid and nonassessable.

Anti-Takeover Effects of Various Provisions of Delaware Law and Fortress Biotech's Certificate of Incorporation and Bylaws

Provisions of the General Corporation Law of the State of Delaware ("DGCL") and our Certificate of Incorporation and Bylaws could make it more difficult to acquire Fortress Biotech by means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers and directors. These provisions, including those summarized below, may encourage certain types of coercive takeover practices and takeover bids.

Delaware Anti-Takeover Statute. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a period of three years following the time the person became an interested stockholder, unless the business combination or the acquisition of shares that resulted in a stockholder becoming an interested stockholder is approved in a prescribed manner. Generally, a "business combination" includes a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. Generally, an "interested stockholder" is a person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status did own) 15% or more of a corporation's voting stock. However, our Certificate of Incorporation provides that we are not subject to the anti-takeover provisions of Section 203 of the DGCL.

Removal. Subject to the rights of any holders of any outstanding series of our preferred stock, stockholders may remove our directors with or without cause, by a vote of the stockholders. Removal will require the affirmative vote of holders of a majority of our voting stock.

Size of Board and Vacancies. Our Bylaws provide that the number of directors be fixed exclusively by the board of directors. Any vacancies may only be filled by a majority of the remaining directors, even if less than a quorum is present, or by a sole remaining director. Any director appointed to fill a vacancy on our board of directors will be appointed until the next annual meeting and until his or her successor has been elected and qualified.

Requirements for Advance Notification of Stockholder Nominations and Proposals. Our Bylaws establish advance notice procedures with respect to stockholder proposals and nomination of candidates for election as directors other than nominations made by or at the direction of its board of directors or a committee of our board of directors.

Undesignated Preferred Stock. Our board of directors is authorized to issue up to 15,000,000 shares of preferred stock without additional stockholder approval, which preferred stock could have voting rights or conversion rights that, if exercised, could adversely affect the voting power of the holders of Common Stock. The issuance of

shares of preferred stock may have the effect of delaying, deferring or preventing a change in control of the Company without any action by the Company's stockholders.

Oaktree Warrants Held by the Oaktree Selling Stockholders and the Warrants

Exercisability

The Oaktree Warrants became exercisable on June 13, 2023 and will expire on August 27, 2030. The November 2023 Warrants became exercisable on upon issuance and will expire November 14, 2028. The December 2023 Warrants became exercisable upon issuance and will expire on January 3, 2029.

Exercise Limitation

A holder will not have the right to exercise any portion of the Oaktree Warrants if the holder (together with its affiliates and certain related parties) would beneficially own in excess of 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Oaktree Warrants.

A holder will not have the right to exercise any portion of the Warrants if the holder (together with its affiliates and certain related parties) would beneficially own in excess of 4.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants. However, any holder of the Warrants may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days following notice from the holder to us.

Exercise Price

The exercise price per whole share of Common Stock purchasable upon exercise of the Oaktree Warrants, the November 2023 Warrants and the December 2023 Warrants is equal to \$7.2392, \$1.65 and \$3.21, respectively. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our Common Stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.

Transferability

Subject to applicable laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent.

Exchange Listing

The Warrants are not listed on any securities exchange or nationally recognized trading system.

Fundamental Transactions

In the event of a fundamental transaction, as described in the Warrants and generally including any reorganization, recapitalization or reclassification of our Common Stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding Common Stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding Common Stock, the holders of the Warrants will be entitled to receive upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Warrants immediately prior to such fundamental transaction. As an alternative, the holders of the November 2023 Warrants and the December 2023 Warrants may, at their option, in the event of a fundamental transaction, exercisable at any time concurrently with, or within 30 days after, the consummation of the fundamental transaction (or, if later, the date of the public announcement of the applicable fundamental transaction), cause the Company to purchase the unexercised portion of the November 2023 Warrants and the December 2023 Warrants from the holder by paying to the holder an amount of cash equal to the Black Scholes Value (as defined in the November 2023 Warrants and the December 2023 Warrants) of the remaining unexercised portion of the November 2023 Warrants and the December 2023 Warrants on the date of the consummation of such fundamental transaction.

Rights as a Stockholder

Except as otherwise provided in the Warrants or by virtue of such holder's ownership of shares of our Common Stock, the holder of a Warrant does not have the rights or privileges of a holder of our Common Stock, including any voting rights, until the holder exercises the Warrant.

Governing Law

The Warrants are governed by New York law.

CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS

The following discussion summarizes certain U.S. federal income tax considerations of the acquisition, ownership and disposition of the Common Stock offered by this prospectus but does not purport to be a complete analysis of all potential tax effects. This discussion does not address effects of other U.S. federal tax laws, such as estate and gift tax laws, or of state, local, non-U.S. or other tax considerations that may be relevant to a purchaser or holder of the Common Stock in light of their particular circumstances. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the "Code"), the Treasury regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the "IRS"), in each case as of the date hereof. These authorities may change, possibly with retroactive effect, or may be subject to differing interpretations that may adversely affect a holder of the Common Stock. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the acquisition, ownership and disposition of the Common Stock.

This discussion is limited to holders that hold the Common Stock as a capital asset within the meaning of Section 1221 of the Code (generally property held for investment). This discussion does not describe all of the U.S. federal income tax consequences that may be relevant to a holder in light of its particular circumstances, including the impact of the alternative minimum tax and of the Medicare contribution tax on net investment income. In addition, it does not address consequences for holders subject to special rules, including without limitation:

- U.S. expatriates and former citizens or long-term residents of the United States;
- persons holding the Common Stock as part of a hedge, straddle, conversion, or other integrated transaction;
- banks, insurance companies, and other financial institutions;
- brokers, dealers or traders in securities;
- “controlled foreign corporations,” “passive foreign investment companies,” and corporations that accumulate earnings;
- to avoid U.S. federal income tax;
- S corporations or entities or arrangements that are treated as partnerships for U.S. federal income tax purposes (and investors therein);
- tax-exempt organizations or governmental organizations;
- real estate investment trusts or regulated investment companies;
- U.S. persons whose functional currency is not the U.S. dollar;
- persons subject to special tax accounting rules;
- persons who hold or receive the Common Stock pursuant to the exercise of any employee stock option or otherwise as compensation;
- persons deemed to sell our Common Stock under the constructive sale provisions of the Code;
- tax-qualified retirement plans, individual retirement accounts or other tax-deferred accounts; and
- “qualified foreign pension funds” as defined in Section 897(l)(2) of the Code.

If a partnership (or any other entity treated as a partnership for U.S. federal income tax purposes) holds the Common Stock, the U.S. federal income tax treatment of a partner of that partnership generally will depend upon the status of the partner and the activities of the partnership. If you are a partnership or a partner of a partnership holding the Common Stock, you should consult your tax advisors as to the particular U.S. federal income tax consequences of holding and disposing of the Common Stock.

This discussion is for information purposes only and is not tax advice. You should consult your own independent tax advisor concerning the application of the U.S. federal income tax laws to your particular circumstances as well as any tax consequences for the acquisition, ownership, or disposition of the Common Stock arising under other U.S. federal tax laws and the laws of any state, local or non-U.S. tax jurisdiction or under any applicable income tax treaty.

For purposes of this discussion, a “U.S. holder” is a beneficial owner of our Common Stock that, for U.S. federal income tax purposes, is or is treated as:

- an individual who is a citizen or resident of the United States;
- a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia;
- an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
- a trust that (i) is subject to the primary supervision of a U.S. court and the control of one or more “United States persons” (within the meaning of Section 7701(a)(30) of the Code) or (ii) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.

A “non-U.S. holder” is any beneficial owner of our Common Stock that is not a U.S. holder.

U.S. Holders

Distributions in General

If distributions are made with respect to the Common Stock, such distributions will be treated as dividends to the extent of our current or accumulated earnings and profits as determined under the Code. Subject to customary conditions and limitations, dividends will be eligible for the dividends-received deduction in the case of U.S. holders that are (or are treated for U.S. federal income tax purposes) as corporations. Dividends paid to non-corporate U.S. holders generally will qualify for taxation at preferential rates if those holders meet certain holding period and other applicable requirements. Dividends received by non-corporate U.S. holders may also be subject to the additional 3.8% tax on net investment income. Any portion of a distribution that exceeds our current and accumulated earnings and profits will first be applied to reduce a U.S. holder’s tax basis in the Common Stock, but not below zero. Distributions in excess of our current and accumulated earnings and profits and in excess of a U.S. holder’s tax basis in its shares will be taxable as gain from the disposition of the Common Stock, the tax treatment of which is discussed below.

Extraordinary Dividends

Dividends that exceed certain thresholds in relation to a U.S. holder’s tax basis in the Common Stock could be characterized as “extraordinary dividends” under Section 1059 of the Code. Corporate U.S. holders that have held our Common Stock for two years or less before the dividend announcement date and that receive an extraordinary dividend will generally be required to reduce their tax basis in the stock by the nontaxed portion of the dividend due to the dividends-received deduction. If the amount of reduction exceeds the U.S. holder’s tax basis in the stock, the excess will be taxable as gain from the disposition of the stock, the tax treatment of which is discussed below. Non-corporate U.S. holders that receive an extraordinary dividend will be required to treat any losses on the sale of our Common Stock as long-term capital losses to the extent of the extraordinary dividends such U.S. holders receive that qualify for taxation at the preferential rates discussed above under “— Distributions in General.” U.S. holders are urged to consult their tax advisors with respect to the eligibility for and amount of any dividend received deduction and the application of Section 1059 of the Code to any dividends they receive.

Disposition of Common Stock by Sale, Exchange or Redemption

Upon any sale or disposition (other than certain redemptions, as discussed below) of the Common Stock, a U.S. holder generally will recognize capital gain or loss equal to the difference between the amount realized by the U.S. holder and the U.S. holder's adjusted tax basis in the Common Stock. Such capital gain or loss will be long-term capital gain or loss if the U.S. holder's holding period for the Common Stock is longer than one year. Non-corporate U.S. holders may be eligible for preferential tax rates on long-term capital gains but also may be subject to the additional 3.8% tax on net investment income. The deductibility of capital losses is subject to limitations.

A redemption of the Common Stock will be treated as a sale or exchange described in the preceding paragraph if the redemption, based on the facts and circumstances, is treated for U.S. federal income tax purposes as (i) a "complete termination" of your interest in the Common Stock, (ii) a "substantially disproportionate" redemption of your Common Stock, or (iii) is "not essentially equivalent to a dividend," each within the meaning of Section 302 of the Code. In determining whether any of these tests has been met, you must take into account not only the Common Stock and other equity interests that you actually own but also other equity interests that you constructively own under U.S. federal income tax rules.

If you meet none of the alternative tests described above, the redemption will be treated as a distribution subject to the rules described under "—Distributions In General." If a redemption of the Common Stock is treated as a distribution that is taxable as a dividend, you are urged to consult your tax advisor regarding the allocation of your tax basis as between the redeemed and remaining shares of Common Stock.

Information Reporting and Backup Withholding

We or an applicable withholding agent will report to our U.S. holders and the IRS the amount of dividends (including deemed dividends) paid during each year and the amount of any tax withheld with respect to the Common Stock. Certain non-corporate U.S. holders may be subject to U.S. backup withholding at a rate of 28% on payments of dividends on the Common Stock unless the holder furnishes the payor or its agent with a taxpayer identification number, certified under penalties of perjury, and certain other information or otherwise establishes an exemption from backup withholding. Backup withholding tax is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a U.S. holder's U.S. federal income tax liability, provided the U.S. holder timely furnishes the required information to the IRS.

Non-U.S. Holders

Distributions

If distributions are made with respect to the Common Stock, such distributions will be treated as dividends to the extent of our current or accumulated earnings and profits as determined under the Code and may be subject to withholding as discussed below. Any portion of a distribution that exceeds our current and accumulated earnings and profits will first be applied to reduce the Non-U.S. holder's basis in the Common Stock, but not below zero. If the distribution exceeds our current and accumulated earnings and profits and the Non-U.S. holder's basis, the excess will be treated as gain from the disposition of the Common Stock, the tax treatment of which is discussed below.

In addition, if we are classified as a U.S. real property holding corporation (a "USRPHC") within the meaning of Section 897(c) of the Code and any distribution exceeds our current and accumulated earnings and profits, we will need to satisfy our withholding requirements either by (a) treating the entire distribution (even if in excess of earnings and profits) as a dividend subject to the withholding rules described below and withhold at a minimum rate of 15% or such lower rate as may be specified by an applicable income tax treaty for distributions from a USRPHC; or (b) treating (i) only the amount of the distribution equal to our reasonable estimate of our current and accumulated earnings and profits as a dividend subject to the withholding rules in the following paragraph; and (ii) the excess portion of the distribution as subject to withholding at a rate of 15% (or such lower rate as may be specified by an applicable income tax treaty), as if such excess were the result of a sale of shares in a USRPHC, with a credit generally allowed against the Non-U.S. holder's U.S. federal income tax liability for the tax withheld from such excess. We believe that we currently are not a USRPHC, and we do not expect to become a USRPHC for the foreseeable future (see discussion of USRPHCs below under "—Disposition of Common Stock, Including Redemptions").

Dividends (including amounts distributed by a USRPHC and subject to withholding as dividends per the preceding paragraph) paid to a Non-U.S. holder of the Common Stock will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. However, dividends that are treated as being effectively connected with the conduct of a trade or business by the Non-U.S. holder within the United States (and, where a tax treaty applies, are attributable to a permanent establishment maintained by the Non-U.S. holder in the United States) are not subject to this withholding tax, provided that certain certification and disclosure requirements are satisfied including completing IRS Form W-8ECI (or other applicable form). Instead, such dividends are subject to U.S. federal income tax on a net income basis in the same manner as if the Non-U.S. holder were a United States person (as defined under the Code), unless an applicable income tax treaty provides otherwise. Any such effectively connected dividends received by a foreign corporation may be subject to an additional "branch profits tax" at a 30% rate or such lower rate as may be specified by an applicable income tax treaty.

A Non-U.S. holder of the Common Stock who wishes to claim the benefit of an applicable treaty rate and avoid backup withholding for dividends, as discussed below, will be required to (i) complete IRS Form W-8BEN or Form W-8BEN-E (or other applicable form) and certify under penalty of perjury that such holder is not a United States person as defined under the Code and is eligible for treaty benefits, or (ii) if the Common Stock is held through certain foreign intermediaries, satisfy the relevant certification requirements of applicable Treasury regulations. A Non-U.S. holder of the Common Stock eligible for a reduced rate of U.S. withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the U.S. Internal Revenue Service.

Disposition of Common Stock, Including Redemptions

Any gain realized by a Non-U.S. holder on the disposition of the Common Stock generally will not be subject to U.S. federal income or withholding tax unless:

- the gain is effectively connected with the conduct of a trade or business by the Non-U.S. holder in the United States (and, if required by an applicable income tax treaty, attributable to a permanent establishment maintained by the Non-U.S. holder in the United States);
- the Non-U.S. holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition, and certain other conditions are met; or
- we are or have been a USRPHC, as defined in Section 897(c) of the Code, and a Non-U.S. holder owned directly or pursuant to applicable attribution rules at any time during the five-year period ending on the date of disposition more than 5% of the Common Stock — assuming that the Common Stock is regularly traded on an established securities market, within the meaning of Section 897(c)(3) of the Code.

A Non-U.S. holder described in the first bullet point immediately above will generally be subject to tax on the gain derived from the sale under regular graduated U.S. federal income tax rates in the same manner as if the Non-U.S. holder were a United States person as defined under the Code, and, if it is a corporation, may also be subject to branch profits tax equal of 30% (generally applicable to its effectively connected earnings and profits) or at such lower rate as may be specified by an applicable income tax treaty.

An individual Non-U.S. holder described in the second bullet point immediately above will be subject to a flat 30% tax (or at such reduced rate as may be provided by an

A Non-U.S. holder described in the third bullet point above will be subject to U.S. federal income tax under regular graduated U.S. federal income tax rates with respect to the gain realized in the same manner as if the Non-U.S. holder were a United States person as defined under the Code. A corporation is a USRPHC if it is a U.S. corporation and the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business. We believe that we currently are not a USRPHC for U.S. federal income tax purposes, and we do not expect to become a USRPHC for the foreseeable future. Our Common Stock will be listed on the NASDAQ Capital Market and we believe that, for as long as we continue to be so listed, our Common Stock will be treated as regularly traded on an established securities market. However, if we become a USRPHC and our Common Stock is regularly traded on an established securities market, a Non-U.S. holder generally will be subject to U.S. federal income tax on any gain from the disposition of such stock if such Non-U.S. holder has owned or is deemed to have owned more than 5% of our Common Stock, at any time within the shorter of the five-year period preceding the disposition or such holder's holding period for such stock.

If a Non-U.S. holder is subject to U.S. federal income tax on any sale, exchange, redemption (except as discussed below), or other disposition of the Common Stock, the Non-U.S. holder will recognize capital gain or loss equal to the difference between the amount realized by the Non-U.S. holder and the Non-U.S. holder's adjusted tax basis in the Common Stock. Such capital gain or loss will be long-term capital gain or loss if the Non-U.S. holder's holding period for the Common Stock is longer than one year. A Non-U.S. holder should consult its own independent tax advisors with respect to applicable tax rates and netting rules for capital gains and losses. Certain limitations exist on the deduction of capital losses by both corporate and non-corporate taxpayers.

If a Non-U.S. holder is subject to U.S. federal income tax on any disposition of the Common Stock, a redemption of shares of the Common Stock will be a taxable event. If the redemption is treated as a sale or exchange, instead of as a dividend, a Non-U.S. holder generally will recognize capital gain or loss, equal to the difference between the amount of cash received and fair market value of any property received and the Non-U.S. holder's adjusted tax basis in the Common Stock redeemed (except that to the extent that any cash received is attributable to any accrued but unpaid dividends), and such capital gain or loss will be long-term capital gain or loss if the Non-U.S. holder's holding period for such Common Stock exceeds one year. A payment made in redemption of the Common Stock may be treated as a dividend (subject to taxation as discussed above under "*Disposition of Common Stock, Including Redemptions*"), rather than as payment in exchange for the Common Stock, in the same circumstances discussed above under "*Disposition of Common Stock, Including Redemptions*." Each Non-U.S. holder of the Common Stock should consult its own independent tax advisors to determine whether a payment made in redemption of the Common Stock will be treated as a dividend or as payment in exchange for the Common Stock.

Information Reporting and Backup Withholding

We must annually report to the IRS and to each Non-U.S. holder the amount of dividends (including constructive dividends) paid to such Non-U.S. holder and the tax withheld with respect to such dividends, regardless of whether withholding was required. Copies of the information returns reporting such dividends and withholding may also be made available under the provisions of an applicable tax treaty or agreement with the tax authorities in the country in which the non-U.S. holder resides. U.S. backup withholding will generally apply to the payment of dividends to non-U.S. holders unless such non-U.S. holders furnish to the payor an IRS Form W-8BEN or Form W-8BEN-E (or other applicable form) or otherwise establish an exemption.

Payment by a U.S. office of a broker of the proceeds of a sale of shares of our Common Stock is subject to both backup withholding and information reporting unless the non-U.S. holder, or beneficial owner thereof, as applicable, certifies that it is a non-U.S. holder on Form W-8BEN or Form W-8BEN-E (or other suitable substitute or successor form), or otherwise establishes an exemption. Subject to certain exceptions, backup withholding and information reporting generally will not apply to a payment of proceeds from the sale of shares of our Common Stock if such sale is effected through a foreign office of a broker, provided that the broker does not have certain U.S. connections. Any amount withheld under the backup withholding rules from a payment to a non-U.S. holder is allowable as a credit against such holder's U.S. federal income tax liability (if any), which may entitle the holder to a refund if in excess of such liability, provided that the holder timely provides the required information to the IRS. Non-U.S. holders are urged to consult their own tax advisers regarding the application of backup withholding in their particular circumstances and the availability of and procedure for obtaining an exemption from backup withholding under current Treasury Regulations.

Foreign Account Tax Compliance Act

Sections 1471 to 1474 of the Code (such sections, and the Treasury Regulations and administrative guidance issued thereunder, commonly referred to as FATCA) impose a 30% U.S. withholding tax on certain "withholdable payments" made to a "foreign financial institution" or a "nonfinancial foreign entity." "Withholdable payments" include payments of dividends and the gross proceeds from a disposition of certain property (such as shares of our Common Stock), if such disposition occurs after December 31, 2018. In general, if a holder is a "foreign financial institution" (which includes investment entities such as hedge funds and private equity funds), the 30% withholding tax will apply to withholdable payments made to such holder, unless such holder enters into an agreement with the U.S. Department of Treasury to collect and provide substantial information regarding its U.S. account holders, including certain account holders that are foreign entities with U.S. owners, and to withhold 30% on certain "pass-through payments." If such holder is a "non-financial foreign entity," FATCA also generally will impose a withholding tax of 30% on withholdable payments made to such holder unless the holder provides the withholding agent with a certification that it does not have any "substantial United States owners" or a certification identifying its direct and indirect substantial United States owners. Intergovernmental agreements between the United States and a holder's resident country may modify some of the foregoing requirements.

Although withholding under FATCA would also have applied to payments of gross proceeds from the sale or other disposition of the Common Stock on or after January 1, 2019, Treasury Regulations proposed in late 2018 eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued.

We will not pay any additional amounts to holders of the Common Stock in respect of any amounts withheld. Non-U.S. holders should consult their own tax advisers with respect to the U.S. federal income tax consequences of FATCA on their ownership and disposition of shares of our Common Stock.

Documentation that holders provide in order to be treated as FATCA compliant may be reported to the IRS and other tax authorities, including information about a holder's identity, its FATCA status and if applicable, its direct and indirect U.S. owners. Prospective investors should consult their tax advisers about how information reporting and the possible imposition of withholding tax under FATCA may apply to their investment in the Common Stock.

PLAN OF DISTRIBUTION

Shares of Common Stock Issuable Upon Exercise of the Warrants

We are offering an aggregate of up to 9,188,305 shares of our Common Stock issuable upon the exercise of:

- The November 2023 Warrants; and
- The December 2023 Warrants.

in each case pursuant to the terms of the respective warrant agreements, which are incorporated by reference into this prospectus. See the sections entitled “*Where You Can Find More Information*” and “*Incorporation of Certain Information by Reference*.”

Selling Stockholders (Holders of the Oaktree Warrants, 2023 Shares, and 2024 Shares)

The Selling Stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling Resale Shares or interests in Resale Shares received after the date of this prospectus from a Selling Stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their Resale Shares or interests in Resale Shares on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

The Selling Stockholders may use any one or more of the following methods when disposing of shares or interests therein:

- ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
- block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
- purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
- an exchange distribution in accordance with the rules of the applicable exchange;
- privately negotiated transactions;
- short sales effected after the date the registration statement of which this prospectus is a part is declared effective by the SEC;
- through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
- broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share;
- a combination of any such methods of sale; and
- any other method permitted by applicable law.

The Selling Stockholders may, from time to time, pledge or grant a security interest in some or all of the Resale Shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Resale Shares, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this prospectus. The Selling Stockholders also may transfer the Resale Shares in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

In connection with the sale of shares of our Common Stock or interests therein under this prospectus, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of shares of our Common Stock in the course of hedging the positions they assume. The Selling Stockholders may also sell shares of our Common Stock short and deliver these securities to close out their short positions, or loan or pledge the shares to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The aggregate proceeds to the Selling Stockholders from the sale of the Resale Shares offered by them will be the purchase price of the Resale Shares less discounts or commissions, if any. Each of the Selling Stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of Resale Shares to be made directly or through agents. We will not receive any of the proceeds from this offering.

The Selling Stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act of 1933, provided that they meet the criteria and conform to the requirements of that rule.

The Selling Stockholders and any underwriters, broker-dealers or agents that participate in the sale of the Resale Shares or interests therein may be “underwriters” within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling Stockholders who are “underwriters” within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act.

To the extent required, the shares of our Common Stock to be sold, the names of the Selling Stockholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.

In order to comply with the securities laws of some states, if applicable, the Resale Shares may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the Common Stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

We have advised the Selling Stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the Selling Stockholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as it may be supplemented or amended

from time to time) available to the Selling Stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.

We have agreed to indemnify the Selling Stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.

We have agreed with the Selling Stockholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement or (2) the date on which all of the shares may be sold without restriction pursuant to Rule 144 of the Securities Act.

LEGAL MATTERS

Certain legal matters will be passed upon for us by Troutman Pepper Locke LLP, Charlotte, North Carolina. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.

EXPERTS

The consolidated financial statements of Fortress Biotech, Inc. as of December 31, 2024 and December 31, 2023, and for each of the years in the two-year period ended December 31, 2024, have been incorporated by reference herein and in the registration statement, in reliance on the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as expert in accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the Common Stock offered hereby. This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules thereto. For further information with respect to the Company and its Common Stock, reference is made to the registration statement and the exhibits and any schedules filed therewith. Statements contained in this prospectus as to the contents of any contract or other document referred to are not necessarily complete and in each instance, if such contract or document is filed as an exhibit, reference is made to the copy of such contract or other document filed as an exhibit to the registration statement, each statement being qualified in all respects by such reference.

We are subject to the information reporting requirements of the Exchange Act, and we file periodic reports and other information with the SEC. These filings include our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and proxy statements on Schedule 14A, as well as any amendments to those reports and proxy statements, which are available free of charge through our website as soon as reasonably practicable after we file them with, or furnish them to, the SEC. Our Internet website address is www.fortressbiotech.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus. You should not rely on any such information in making your decision whether to purchase our securities. The SEC also maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding us and other issuers that file electronically with the SEC.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

The SEC allows us to “incorporate by reference” information we file with it into this prospectus, which means that we can disclose important information to you by referring you to other documents. The information incorporated by reference is considered to be part of this prospectus, and information that we file later with the SEC and incorporate by reference will automatically update and supersede this information. We incorporate by reference into this prospectus the documents listed below and all future filings made by us with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, except for information “furnished” under Items 2.02, 7.01 or 9.01 on Form 8-K or other information “furnished” to the SEC which is not deemed filed and not incorporated in this prospectus, until the termination of the offering of securities described in the applicable prospectus supplement.

We hereby incorporate by reference the following documents:

- (a) [our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025;](#)
- (b) our Current Reports on Form 8-K filed with the SEC on [January 6, 2025](#), [January 16, 2025](#) and [March 10, 2025](#); and

(c) the description of our Common Stock included in our registration statements on Form 8-A12B, filed with the SEC on [December 7, 2011](#) and [November 7, 2017](#), and any amendment or report filed for the purpose of further updating such descriptions.

Any statement contained in this prospectus or in a document incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

Any statement contained in this prospectus or in a document incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. You should direct any requests for documents in writing to: Fortress Biotech, Inc., 1111 Kane Concourse Suite 301 Bay Harbor Islands, FL 33154, Attention: Corporate Secretary, tel: 781-652-4500. These documents are also available on the Investors section of our website, which is located at www.fortressbiotech.com, or as described under “Where You Can Find More Information” above. The reference to our website address does not constitute incorporation by reference of the information contained on our website into this prospectus.

You should rely only on information contained in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference in this prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.



Fortress Biotech, Inc.

**9,188,305 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants
2,103,887 Shares of Common Stock for Resale by Selling Stockholders**

PROSPECTUS

, 2025

**PART II
INFORMATION NOT REQUIRED IN PROSPECTUS**

Item 13. Other Expenses of Issuance and Distribution

	Amount to Be Paid
U.S. Securities and Exchange Commission registration fee	\$ -
Legal fees and expenses	\$ 25,000
Accounting fees and expenses	\$ 25,000
Total	\$ 50,000

Item 14. Indemnification of Directors and Officers

Under the General Corporation Law of the State of Delaware (“DGCL”), a corporation may include provisions in its certificate of incorporation that will relieve its directors of monetary liability for breaches of their fiduciary duty to the corporation, except under certain circumstances, including a breach of the director’s duty of loyalty, acts or omissions of the director not in good faith or which involve intentional misconduct or a knowing violation of law, the approval of an improper payment of a dividend or an improper purchase by the corporation of stock or any transaction from which the director derived an improper personal benefit. The Company’s Amended and Restated Certificate of Incorporation eliminates the personal liability of directors to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director with certain limited exceptions set forth in the DGCL.

Section 145 of the DGCL grants to corporations the power to indemnify each officer and director against liabilities and expenses incurred by reason of the fact that he or she is or was an officer or director of the corporation if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The Company’s Amended and Restated Certificate of Incorporation and Bylaws provide for indemnification of each officer and director of the Company to the fullest extent permitted by the DGCL. Section 145 of the DGCL also empowers corporations to purchase and maintain insurance on behalf of any person who is or was an officer or director of the corporation against liability asserted against or incurred by him in any such capacity, whether or not the corporation would have the power to indemnify such officer or director against such liability under the provisions of Section 145 of the DGCL.

Item 15. Recent Sales of Unregistered Securities

Set forth below is information regarding all securities sold by us since March 31, 2022, the offer and sale of which were not registered under the Securities Act. Also included is the consideration received by us for such securities and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed.

On July 25, 2024, we entered into the senior secured credit agreement dated as of July 25, 2024 (the “2024 Credit Agreement”) with Oaktree and lenders from time to time party thereto, in connection with which we granted to Oaktree and certain of its affiliates warrants to purchase 506,390 shares of Common Stock at an exercise price per share of \$1.65 (as adjusted from \$2.0735) (the “2024 Warrants”). The 2024 Warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offerings and pro rata distributions. The exercise price of the 2024 Warrants will also be adjusted if, while the 2024 Warrants are outstanding, the Company engages in any transaction involving the issuance or sale of shares of common stock or equivalent securities at an effective price per share less than the exercise price of the 2024 Warrants then in effect (such lower price, the “Base Share Price”). In such case, the exercise price of the 2024 Warrants will be reduced to equal the Base Share Price. The 2024 Warrants became immediately exercisable upon issuance, will expire on July 25, 2031 and may be net exercised for no cash payment at the holder’s election.

In addition, in connection with the 2024 Credit Agreement, we entered into a registration rights agreement with Oaktree and certain of its affiliates (the “2024 Registration Rights Agreement”), in which we agreed to prepare and file with the SEC a registration statement with respect to resales of the 2024 Warrant Shares purchased by Oaktree and certain of its affiliates in connection with the 2024 Credit Agreement. Accordingly, the registration statement of which this prospectus is a part relates to the offer and resale of the 2024 Warrant Shares.

On June 27, 2024, the Company issued 2,028,345 shares of its Common Stock to the former holders of the Urica Preferred Stock. The issuance of the Shares was in satisfaction of obligations under the Dividend and Exchange Agreement. On June 27, 2024, based on the formula provided by the terms of the Urica Preferred Stock, Fortress elected to issue Shares of Common Stock, rather than pay cash, and paid \$20,747.62 in lieu of fractional shares and for accumulated and unpaid dividends that would otherwise have been payable in Common Stock, upon its receipt of all of the issued and outstanding shares of Urica Preferred Stock from the prior holders of such Urica Preferred Stock. The foregoing issuances were made in a transaction exempt from registration under the Securities Act pursuant to Section 4(a) thereof.

On September 19, 2024, in connection with a registered direct offering and private placement by the Company, we entered into certain purchase agreements, each dated September 19, 2024, by and among the Company and the purchasers thereto (the “PIPE Purchase Agreements”). Pursuant to the PIPE Purchase Agreements, we issued warrants to purchase 4,702,753 shares of Common Stock at an exercise price per share of \$1.84 (the “PIPE Warrants”). The PIPE Warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offerings and pro rata distributions. The PIPE Warrants become exercisable on March 23, 2025, will expire on March 23, 2030 and may be net exercised for no cash payment at the holder’s election. Additionally, pursuant to the PIPE Purchase Agreement with Lindsay A. Rosenwald, M.D., our Chairman, President and Chief Executive Officer (the “Chairman”), we issued 763,359 shares of Common Stock at a price per share of \$1.84. Accordingly, the registration statement of which this prospectus is a part relates to the offer and resale of the shares of Common Stock issuable upon the exercise of the PIPE Warrants and the Common Stock issued to our Chairman.

II-2

Item 16. Exhibits and Financial Statement Schedules

The exhibits to the Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.

EXHIBIT INDEX

Exhibit Number	Description
<u>3.1</u>	<u>Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. (formerly Coronado Biosciences, Inc.) dated April 21, 2010 (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 10 (file No. 000-54463) filed with the SEC on July 15, 2011).</u>
<u>3.2</u>	<u>First Certificate of Amendment to Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated May 20, 2011 (incorporated by reference to Exhibit 3.2 of the Registrant’s Form 10 (file No. 000-54463) filed with SEC on July 15, 2011).</u>
<u>3.3</u>	<u>Second Certificate of Amendment to Amended and Restated Certificate of Incorporation, as amended, of Fortress Biotech, Inc. dated October 1, 2013 (incorporated by reference to Exhibit 3.8 of the Registrant’s Annual Report on Form 10-K (file No. 001-35366) filed with the SEC on March 14, 2014).</u>
<u>3.4</u>	<u>Third Certificate of Amendment to Amended and Restated Certificate of Incorporation, as amended, of Fortress Biotech, Inc. dated April 22, 2015 (incorporated by reference to Exhibit 3.9 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on April 27, 2015).</u>
<u>3.5</u>	<u>Certificate of Designation of Rights and Preferences of the Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on November 7, 2017).</u>
<u>3.6</u>	<u>Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated June 18, 2020 (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on June 19, 2020).</u>
<u>3.7</u>	<u>Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated June 23, 2021 (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on June 23, 2021).</u>
<u>3.8</u>	<u>Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated July 8, 2022, (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on July 11, 2022).</u>
<u>3.9</u>	<u>Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated October 9, 2023 (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on October 10, 2023).</u>
<u>3.10</u>	<u>Fourth Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with SEC on June 25, 2024).</u>
<u>4.1</u>	<u>Specimen certificate evidencing shares of common stock, filed as Exhibit 4.1 to Form 10-12G on July 15, 2011 (File no. 000-54463) and incorporated herein by reference.</u>
<u>4.2</u>	<u>Certificate of Designation of Rights and Preferences 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on November 7, 2017).</u>

II-3

<u>4.3</u>	<u>Certificate of Amendment to the Certificate of Designations of Rights and Preferences of the Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock under the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated June 18, 2020 (incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on June 19, 2020).</u>
<u>4.4</u>	<u>Description of Securities of Fortress Biotech, Inc. (incorporated by reference to Exhibit 4.4, of the Registrant’s Annual Report on Form 10-K (file No. 001-35366) filed with the SEC on March 31, 2025).</u>
<u>4.5</u>	<u>Form of Amended and Restated Warrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on June 16, 2023).</u>
<u>4.6</u>	<u>Form of Warrant (Incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on November 14, 2023).</u>
<u>4.7</u>	<u>Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on January 3, 2024).</u>
<u>4.8</u>	<u>Form of Warrant issued to certain affiliates of Oaktree Fund Administration, LLC on July 25, 2024 (incorporated by reference to Exhibit 4.8 of the Registrant’s Registration Statement on Form S-1 (Reg. No. 33-282384) filed with the SEC on September 27, 2024).</u>
<u>4.9</u>	<u>Form of PIPE Warrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on September 23, 2024).</u>
<u>5.1</u>	<u>Opinion of Troutman Pepper Locke LLP.*</u>
<u>10.1</u>	<u>Amended and Restated Consulting Agreement, entered into as of January 1, 2019, by and between the Registrant and Eric Rowinsky (incorporated by reference to Exhibit 10.3 of the Registrant’s Annual Report on Form 10-K (file No. 001-35366) filed with the SEC on March 18, 2019).#</u>
<u>10.2</u>	<u>Restricted Stock Issuance Agreement, dated as of February 20, 2014, by and between the Registrant and Michael S. Weiss (incorporated by reference to Exhibit 10.55 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on February 26, 2014).#</u>

- [10.3](#) [Form of Indemnification Agreement by and between the Registrant and its officers and directors \(incorporated by reference to Exhibit 10.25 of the Registrant's Form 10 \(file No. 000-54463\) filed with the SEC on August 24, 2011\).#](#)
- [10.4](#) [Restricted Stock Issuance Agreement, dated as of December 19, 2013, by and between the Registrant and Michael S. Weiss \(incorporated by reference to Exhibit 10.57 of the Registrant's Annual Report on Form 10-K \(file No. 001-35366\) filed with the SEC on March 14, 2014\). #](#)
- [10.5](#) [Restricted Stock Issuance Agreement, dated as of December 19, 2013, by and between the Registrant and Lindsay A. Rosenwald, M.D \(incorporated by reference to Exhibit 10.58 of the Registrant's Annual Report on Form 10-K \(file No. 001-35366\) filed with the SEC on March 14, 2014\).](#)
- [10.6](#) [Coronado Biosciences, Inc. Deferred Compensation Plan for Directors, dated March 12, 2015 \(incorporated by reference to Exhibit 10.67 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on March 18, 2015\).#](#)
- [10.7](#) [Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan, as amended \(incorporated by reference to Exhibit 10.38 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on June 12, 2017\).#](#)
- [10.8](#) [Amendment to Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan \(incorporated by reference to Exhibit A of the Registrant's Schedule 14A \(file No. 001-35366\) filed with the SEC on April 30, 2018\).#](#)
- [10.9](#) [Amendment to the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan \(incorporated by reference to Exhibit 10.2 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on June 23, 2023\).#](#)
- [10.10](#) [Fortress Biotech, Inc. Amended and Restated Long-Term Incentive Plan \(incorporated by reference to Exhibit 10.39 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on June 12, 2017\).#](#)
- [10.11](#) [Fortress Biotech, Inc. 2013 Stock Incentive Plan, as amended \(incorporated by reference to Appendix A of the Registrant's Schedule 14-A \(file No. 001-35366\) filed with the SEC on June 4, 2015\).#](#)

II-4

- [10.12](#) [Form of Stock Incentive Plan Award Agreement \(Fortress Biotech, Inc. 2013 Stock Incentive Plan\) \(incorporated by reference to Exhibit 10.60 of the Registrant's Form S-8 \(file No. 333-194588\) filed with the SEC on March 14, 2014\).#](#)
- [10.13](#) [Amendment to the Fortress Biotech, Inc. 2013 Stock Incentive Plan \(incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on June 19, 2020\).#](#)
- [10.14](#) [Amendment to the Fortress Biotech, Inc. 2013 Stock Incentive Plan \(incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on June 27, 2022\).#](#)
- [10.15](#) [Amendment to the Fortress Biotech, Inc. 2013 Stock Incentive Plan \(incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on June 23, 2023\).#](#)
- [10.16](#) [Restricted Stock Unit Award Agreement between Fortress Biotech, Inc. and David Jin effective October 26, 2022 \(incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on October 28, 2022\).#](#)
- [10.17](#) [Indemnification Agreement between Fortress Biotech, Inc. and Lucy Lu, M.D. dated as of December 14, 2022 \(incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on December 19, 2022\).#](#)
- [10.18](#) [At Market Issuance Sales Agreement between the Company and Cantor Fitzgerald & Co., Oppenheimer & Co. Inc., H.C. Wainwright & Co., LLC, B. Riley FBR, Inc., and Dawson James Securities, Inc., dated May 29, 2020 \(incorporated by reference to Exhibit 1.1 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on May 29, 2020\).](#)
- [10.19](#) [Amendment to the Fortress Biotech, Inc. 2013 Stock Incentive Plan \(incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on May 29, 2024\).](#)
- [10.20](#) [Amendment to the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan \(incorporated by reference to Exhibit 10.2 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on May 29, 2024\).](#)
- [10.21](#) [Amendment to the Fortress Biotech, Inc. Amended and Restated Long Term Incentive Plan \(incorporated by reference to Exhibit 10.3 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on May 29, 2024\).](#)
- [10.22](#) [Form of Securities Purchase Agreement, dated September 19, 2024, by and among the Company and the purchasers party thereto \(incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on September 23, 2024\).](#)

II-5

- [10.23](#) [Placement Agent Agreement entered into by and between the Company and the Placement Agent, dated September 19, 2024 \(incorporated by reference to Exhibit 10.3 of the Registrant's Current Report on Form 8-K \(file No. 001-35366\) filed with the SEC on September 23, 2024\).](#)
- [10.24](#) [Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on July 25, 2024 \(incorporated by reference to Exhibit 10.34 to the Registrant's Registration Statement on Form S-1 \(Reg. No. 33-282384\) filed with the SEC on September 27, 2024\).](#)
- [10.25](#) [Asset Purchase Agreement, dated as of July 15, 2024, between Urica Therapeutics, Inc. and Crystalys Therapeutics, Inc. \(incorporated by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q \(file No. 001-35366\) filed with the SEC on November 14, 2024\).**](#)
- [10.26](#) [Royalty Agreement, dated as of July 15, 2024, between Urica Therapeutics, Inc. and Crystalys Therapeutics, Inc. \(incorporated by reference to Exhibit 10.5 to the Registrant's Quarterly Report on Form 10-Q \(file No. 001-35366\) filed with the SEC on November 14, 2024\).**](#)
- [21.1](#) [Subsidiaries of the Registrant \(incorporated by reference to Exhibit 21.1 of the Registrant's Annual Report on Form 10-K \(file No. 001-35366\) filed with the SEC on March 31, 2025\).](#)
- [23.1](#) [Consent of Troutman Pepper Hamilton Sanders LLP \(to be included in Exhibit 5.1\).*](#)
- [23.2](#) [Consent of KPMG LLP, Independent Registered Accounting Firm.*](#)
- [24.1](#) [Power of Attorney \(included on signature page to this registration statement.*](#)
- [107](#) [Filing Fee Table.*](#)

* Filed herewith.

** Certain portions of this exhibit have been omitted pursuant to Item 60(b)(10) of Regulation S-K.

Management contract or compensatory plan.

Item 17. Undertakings

(a) The undersigned registrant hereby undertakes:

1. To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
- i. To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

- ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement;
- iii. To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

provided, however, that paragraphs (i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement, or, is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
- 2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
- 3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

II-6

- 4. That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
- 5. That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
 - i. Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
 - ii. Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
 - iii. The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
 - iv. Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b)The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefits plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(h)Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed by the final adjudication of such issue.

II-7

- (i) The undersigned registrant hereby undertakes that:

(1)For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

(2)For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

FORTRESS BIOTECH, INC.

March 31, 2025

By: /s/ Lindsay A. Rosenwald, M.D.
Lindsay A. Rosenwald, M.D.
Chairman, President and Chief Executive Officer
(Principal Executive Officer)

POWERS OF ATTORNEY

Each person whose signature appears below constitutes and appoints Lindsay A. Rosenwald, M.D., his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including pre-effective and post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, including any Registration Statement filed pursuant to Rule 462(b) under the Securities Act of 1933, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of his substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated as of March 31, 2025.

II-8

Signature	Title	Date
<u>/s/ Lindsay A. Rosenwald, M.D.</u> Lindsay A. Rosenwald, M.D.	Chairman of the Board of Directors, President and Chief Executive Officer (Principal Executive Officer)	March 31, 2025
<u>/s/ David Jin</u> David Jin	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	March 31, 2025
<u>/s/ Michael S. Weiss</u> Michael S. Weiss	Executive Vice Chairman, Strategic Development and Director	March 31, 2025
<u>/s/ Jimmie Harvey, Jr., M.D.</u> Jimmie Harvey, Jr., M.D.	Director	March 31, 2025
<u>/s/ Malcolm Hoenlein</u> Malcolm Hoenlein	Director	March 31, 2025
<u>/s/ Dov Klein</u> Dov Klein	Director	March 31, 2025
<u>/s/ J. Jay Lobell</u> J. Jay Lobell	Director	March 31, 2025
<u>/s/ Kevin L. Lorenz, J.D.</u> Kevin L. Lorenz, J.D.	Director	March 31, 2025
<u>/s/ Lucy Lu, M.D.</u> Lucy Lu, M.D.	Director	March 31, 2025

II-9

Troutman Pepper Locke LLP
301 S. College Street, 34th Floor
Charlotte, NC 28202

troutman.com



March 31, 2025

Fortress Biotech, Inc.
1111 Kane Concourse, Suite 301
Bay Harbor Islands, FL 33154

Re: Securities Registered under Registration Statement on Post-Effective Amendment to Form S-3 on Form S-1

Ladies and Gentlemen:

We have acted as counsel to Fortress Biotech, Inc., a Delaware corporation (the “Company”), in connection with the Company’s Post-Effective Amendment No. 1 to Form S-3 on Form S-1 registration statement (the “Registration Statement”), including the prospectus that is part of the Registration Statement (the “Prospectus”), filed on the date hereof, with the U.S. Securities and Exchange Commission (the “Commission”), under the Securities Act of 1933, as amended (the “Securities Act”). The Registration Statement relates to the registration of (i) the offer, sale and issuance of 9,188,305 shares (the “Warrant Shares”) of the Company’s common stock, par value \$0.001 per share (the “Common Stock”) upon the exercise of the outstanding warrants; and (ii) the resale by the selling stockholders named in the Registration Statement (the “Selling Stockholders”) of up to an aggregate of (a) 116,637 shares of Common Stock (the “Oaktree Warrant Shares”) issuable upon the exercise of warrants, as amended, issued to the Selling Stockholders and (b) 1,987,250 shares of Common Stock (the “Urica Shares” together with the Oaktree Warrant Shares, the “Resale Shares”) that were issued to former holders of the 8% Cumulative Redeemable Perpetual Class B Preferred Stock (the “Urica Preferred Stock”) of Urica Therapeutics, Inc. in connection with a Dividend Payment and Exchange Agreement dated as of December 27, 2022 (the “Dividend Agreement”) and pursuant to the terms of Urica Preferred Stock, which Resale Shares may be sold from time to time by the Selling Stockholders. The Registration Statement relates to, and amends in a single post-effective amendment, the following:

- a registration statement on Form S-3 originally filed with the Commission on June 20, 2024, File No. 333-280342;
- a registration statement on Form S-3 originally filed with the Commission on February 10, 2023, File No. 333-269687;
- a registration statement on Form S-3 originally filed with the Commission on November 10, 2023, File No. 333-258145; and
- a registration statement on Form S-3 originally filed with the Commission on November 9, 2020, File No. 333-249983.

Fortress Biotech, Inc.
March 31, 2025
Page 2



This opinion letter is being furnished in accordance with the requirements of Item 16 of Form S-1 and Item 601(b)(5)(i) of Regulation S-K promulgated under the Securities Act. Capitalized terms used and not defined herein shall have the meanings assigned to them in the Registration Statement.

The Resale Shares are described in the Registration Statement. The Warrant Shares are issuable (i) upon exercise of certain warrants, originally issued on November 10, 2023 as part of units, each consisting of one share of Common Stock and one warrant (the “November 2023 Warrants”), and (ii) upon exercise of certain warrants, originally issued on December 29, 2023 as part of units, each consisting of one share of Common Stock and one warrant (the “December 2023 Warrants” together with the November 2023 Warrants, the “Warrants”). The Oaktree Warrant Shares are issuable upon exercise of certain warrants, as amended, granted to Oaktree Fund Administration, LLC (“Oaktree”) and certain of its affiliates (the “Oaktree Warrants”) pursuant to the senior secured credit agreement dated as of August 27, 2020 by and between the Company, Oaktree, as administrative agent, and the lenders from time to time party thereto. The Urica Shares were issued as dividends on, and upon exchange of, the Urica Preferred Stock under the Dividend Agreement.

In connection with this opinion, we have reviewed the corporate proceedings taken by the Company with respect to the offer, sale and issuance of the Warrant Shares upon the exercise of the Warrants and the issue and sale, and registration of the resale of, the Resale Shares. We have also examined and relied upon originals or copies of such corporate records, documents, agreements or other instruments of the Company, and such certificates and records of public officials, and such other documents, as we have deemed necessary or appropriate in connection herewith, including, but not limited to, the Company’s Amended and Restated Certificate of Incorporation, the Company’s Fourth Amended and Restated Bylaws, the November 2023 Warrants, the December 2023 Warrants, the Oaktree Warrants and the Dividend Agreement and terms of the Urica Preferred Stock pursuant to which the Urica Shares were issued. As to all matters of fact (including, without limitation, factual conclusions and characterizations and descriptions of purpose, intention or other state of mind) we have relied entirely upon a certificate of an officer of the Company, and have assumed, without independent inquiry, the accuracy of that certificate.

In rendering this opinion, we have assumed the genuineness and authenticity of all signatures on the original documents; the legal capacity of all natural persons; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as certified or photocopies; the accuracy and completeness of all documents and records reviewed by us; the accuracy, completeness and authenticity of certificates issued by any governmental official, office or agency and the absence of change in the information contained therein from the effective date of any such certificate; and the due authorization, execution and delivery of all documents where authorization, execution and delivery are prerequisites to the effectiveness of such documents, except that we make no such assumption with respect to the Company.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We are not opining as to the applicability thereto, or the effect thereon, of the laws of any other jurisdiction or, in the case of Delaware, any other laws, or as to matters of municipal law or the laws of any local agencies within any states (including "blue sky" or other state securities laws).

Based upon the foregoing, and in reliance thereon, and subject to the limitations, qualifications, assumptions, exceptions and other matters set forth herein, we are of the opinion that, as of the date hereof, (i) the Urica Shares have been duly authorized and validly issued and are fully paid and non-assessable; (ii) the Oaktree Warrant Shares, when issued and delivered upon exercise of the Oaktree Warrants against payment of the exercise price therefor, will be validly issued, fully paid and non-assessable and (iii) the Warrant Shares, when issued and delivered upon exercise of the Warrants against payment of the exercise price therefor, will be validly issued, fully paid and non-assessable.

We assume no obligation to supplement this opinion if any applicable law changes after the date hereof or if we become aware of any fact that might change the opinion expressed herein after the date hereof.

We hereby consent to the filing of this opinion as a part of the Registration Statement and to the reference of our firm under the caption "Legal Matters" in the Prospectus. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission. Except as otherwise set forth herein, this opinion may not be used, circulated, quoted or otherwise referred to for any purpose or relied upon by any other person without the express written permission of this firm.

Very truly yours,

/s/ TROUTMAN PEPPER LOCKE LLP
Troutman Pepper Locke LLP

Consent of Independent Registered Public Accounting Firm

We consent to the use of our report dated March 31, 2025, with respect to the consolidated financial statements of Fortress Biotech, Inc. and subsidiaries, incorporated herein by reference, and to the reference to our firm under the heading "Experts" in the prospectus.

/s/ KPMG LLP

New York, New York
March 31, 2025

Calculation of Filing Fee Tables

Form S-1
(Form Type)Fortress Biotech, Inc.
(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

	Security Type	Security Class Title	Fee Calculation or Carry Forward Rule	Amount Registered	Proposed Maximum Offering Price Per Share	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
Carry Forward Securities								
Fees Previously Paid	Equity	Common Stock, no par value per share	457(c)	2,103,887 ⁽¹⁾	(2)	(2)	(2)	(2)
Fees Previously Paid	Equity	Common Stock, no par value per share	457(o)	9,188,305 ⁽³⁾	(4)	(4)	(4)	(4)
	Total Offering Amounts							\$3,504.79
	Total Fees Previously Paid							\$3,504.79
	Total Fee Offsets							\$0.00
	Net Fees Due							\$0.00

(1) Represents the sum of up to 2,103,887 shares of Common Stock (i) issuable upon exercise of outstanding warrants and (ii) issued under a dividend and exchange agreement between the registrant and a controlled subsidiary and pursuant to the terms of the corresponding preferred stock.

(2) This registration statement registers 2,103,887 shares of Common Stock. These shares were registered on the following registration statements:

- A registration statement on Form S-3 originally filed with the Securities and Exchange Commission ("SEC") on June 20, 2024, File No. 333-280342, at which time a filing fee of \$653.04, computed in accordance with Rule 457(c) under the Securities Act, was paid;
- A registration statement on Form S-3 originally filed with the SEC on February 10, 2023, File No. 333-269687, at which time a filing fee of \$53.55, computed in accordance with Rule 457(c) under the Securities Act, was paid; and
- A registration statement on Form S-3 originally filed with the SEC on November 9, 2020, File No. 333-249983, at which time a filing fee of \$549.86, computed in accordance with Rule 457(c) under the Securities Act, was paid.

(3) Represents the sum of up to 9,188,305 shares of Common Stock issuable upon exercise of outstanding warrants that were publicly sold.

(4) This registration statement registers 9,188,305 shares of Common Stock. These shares were initially registered on a registration statement on Form S-3 originally filed with the SEC on November 10, 2023, File No. 333-258145 registering up to \$125,000,000 in aggregate principal amount of common stock, preferred stock, warrants, debt securities, and units, at which time a filing fee of \$13,637.50, computed in accordance with Rule 457(o) under the Securities Act, was paid. Of which that filing fee amount, \$2,248.34 related to the 9,188,305 offered by Fortress Biotech, Inc.